Efficacy of bupropion alone and in combination with nicotine gum.
paper
Cited
Public
Unavailable
- Authors
- Piper, Megan E; Federman, E Belle; McCarthy, Danielle E; Bolt, Daniel M; Smith, Stevens S; Fiore, Michael C; Baker, Timothy B
- Year
- 2007
- Journal
- Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
- PMID
- 17763111
- DOI
- 10.1080/14622200701540820
- PMCID
- PMC3030120
In this double-blind, placebo-controlled smoking cessation treatment study, 608 participants were randomly assigned to receive active bupropion and active 4-mg gum (AA, n = 228), active bupropion and placebo gum (AP, n = 224), or placebo bupropion and placebo gum (PP, n = 156). Relative to the PP group, the AA and AP groups were each significantly more likely to be abstinent at 1 week, end of treatment, and 6 months but not at 12 months postquit. After the first week postquit there were no differences in abstinence rates between the AA and AP groups. We found no significant individual difference variables that moderated outcome beyond 1 week postquit.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Efficacy of combined nicotine replacement therapy (NRT) and bupropion compared to bupropion alone for smoking cessation: a systematic review and meta-analysis. | Wang M et al. | — | 2026 | → |
| Korean Clinical Practice Guideline of Korean Society for Research on Nicotine and Tobacco (KSRNT) and National Evidence-based Healthcare Collaborating Agency (NECA) on Treatment of Tobacco Use 2024. | Seo YB et al. | — | 2025 | → |
| Antidepressants for smoking cessation. | Hajizadeh A et al. | — | 2023 | → |
| Synthetic contraceptive hormones occlude the ability of nicotine to reduce ethanol consumption in ovary-intact female rats. | Maher EE et al. | — | 2023 | → |
| Varenicline Combined With Oral Nicotine Replacement Therapy and Smartphone-Based Medication Reminders for Smoking Cessation: Feasibility Randomized Controlled Trial. | Sifat M et al. | — | 2023 | → |
| Interactions between reproductive transitions during aging and addiction: promoting translational crosstalk between different fields of research. | Gipson CD et al. | — | 2021 | → |
| Interactions of neuroimmune signaling and glutamate plasticity in addiction. | Gipson CD et al. | — | 2021 | → |
| Interventions for preventing weight gain after smoking cessation. | Hartmann-Boyce J et al. | — | 2021 | → |
| Multiethnic Prediction of Nicotine Biomarkers and Association With Nicotine Dependence. | Bergen AW et al. | — | 2021 | → |
| Natural and synthetic estrogens specifically alter nicotine demand and cue-induced nicotine seeking in female rats. | Maher EE et al. | — | 2021 | → |
| Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis. | Thomas KH et al. | — | 2021 | → |
| Antidepressants for smoking cessation. | Howes S et al. | — | 2020 | → |
| Multiethnic Prediction of Nicotine Biomarkers and Association with Nicotine Dependence | Bergen AW et al. | — | 2020 | — |
| Strain-specific altered nicotine metabolism in 3,3'-diindolylmethane (DIM) exposed mice. | Bloom AJ et al. | — | 2019 | → |
| Diminishing benefit of smoking cessation medications during the first year: a meta-analysis of randomized controlled trials. | Rosen LJ et al. | — | 2018 | → |
| Nicotine dependence is associated with functional variation in FMO3, an enzyme that metabolizes nicotine in the brain. | Teitelbaum AM et al. | — | 2018 | → |
| Use of polygenic risk scores of nicotine metabolism in predicting smoking behaviors. | Chen LS et al. | — | 2018 | → |
| Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. | Schuit E et al. | — | 2017 | → |
| Rationalization of a nanoparticle-based nicotine nanovaccine as an effective next-generation nicotine vaccine: A focus on hapten localization. | Zhao Z et al. | — | 2017 | → |
| Anxiety and Depression in Bidirectional Relations Between Pain and Smoking: Implications for Smoking Cessation. | Zale EL et al. | — | 2016 | → |
| Combination Therapies for Smoking Cessation: A Hierarchical Bayesian Meta-Analysis. | Windle SB et al. | — | 2016 | → |
| [Psychotherapy and pharmacotherapy for harmful tobacco use and tobacco dependency]. | Batra A et al. | — | 2016 | → |
| A New Strategy for Smoking Cessation: Characterization of a Bacterial Enzyme for the Degradation of Nicotine. | Xue S et al. | — | 2015 | → |
| Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date. | Mamoun M et al. | — | 2015 | → |
| Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption. | Bergen AW et al. | — | 2015 | → |
| Gender differences in responses to cues presented in the natural environment of cigarette smokers. | Wray JM et al. | — | 2015 | → |
| Pharmacological Options for Smoking Cessation in Heavy-Drinking Smokers. | Yardley MM et al. | — | 2015 | → |
| Antidepressants for smoking cessation. | Hughes JR et al. | — | 2014 | → |
| Beyond cigarettes per day. A genome-wide association study of the biomarker carbon monoxide. | Bloom AJ et al. | — | 2014 | → |
| Organic cation transporter variation and response to smoking cessation therapies. | Bergen AW et al. | — | 2014 | → |
| Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). | Chen LS et al. | — | 2014 | → |
| The effects of percentile versus fixed criterion schedules on smoking with equal incentive magnitude for initial abstinence. | Romanowich P et al. | — | 2014 | → |
| Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms. | Bloom AJ et al. | — | 2014 | → |
| Does combination pharmacological intervention for smoking cessation prevent post-cessation weight gain? A systemic review. | Yang M et al. | — | 2013 | → |
| Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. | Bergen AW et al. | — | 2013 | → |
| Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. | Chen LS et al. | — | 2012 | → |
| Interventions for preventing weight gain after smoking cessation. | Farley AC et al. | — | 2012 | → |
| Nicotine replacement therapy for smoking cessation. | Stead LF et al. | — | 2012 | → |
| Weight gain in smokers after quitting cigarettes: meta-analysis. | Aubin HJ et al. | — | 2012 | → |
| New methods for tobacco dependence treatment research. | Baker TB et al. | — | 2011 | → |
| The effect of five smoking cessation pharmacotherapies on smoking cessation milestones. | Japuntich SJ et al. | — | 2011 | → |
| Using decision tree analysis to identify risk factors for relapse to smoking. | Piper ME et al. | — | 2011 | → |
| Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. | Mills EJ et al. | — | 2010 | → |
| Development of the Brief Wisconsin Inventory of Smoking Dependence Motives. | Smith SS et al. | — | 2010 | → |
| Racial differences in smoking abstinence rates in a multicenter, randomized, open-label trial in the United States. | Croghan IT et al. | — | 2010 | → |
| Do smokers know what we're talking about? The construct validity of nicotine dependence questionnaire measures. | Japuntich SJ et al. | — | 2009 | → |
| Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis. | Mills EJ et al. | — | 2009 | → |
| Ethical concerns about non-active conditions in smoking cessation trials and methods to decrease such concerns. | Hughes JR | — | 2009 | → |
| Human neuronal acetylcholine receptor A5-A3-B4 haplotypes are associated with multiple nicotine dependence phenotypes. | Baker TB et al. | — | 2009 | → |
| Impact of bupropion and cognitive-behavioral treatment for depression on positive affect, negative affect, and urges to smoke during cessation treatment. | Strong DR et al. | — | 2009 | → |
| Transdisciplinary Tobacco Use Research Centers: research achievements and future implications. | Baker TB et al. | — | 2009 | → |
| Why assigning ongoing tobacco use is not necessarily a conservative approach to handling missing tobacco cessation outcomes. | Nelson DB et al. | — | 2009 | → |
| Assessing dimensions of nicotine dependence: an evaluation of the Nicotine Dependence Syndrome Scale (NDSS) and the Wisconsin Inventory of Smoking Dependence Motives (WISDM). | Piper ME et al. | — | 2008 | → |
| Nicotine replacement therapy for smoking cessation. | Stead LF et al. | — | 2008 | → |
| Refining the tobacco dependence phenotype using the Wisconsin Inventory of Smoking Dependence Motives. | Piper ME et al. | — | 2008 | → |
| Antidepressants for smoking cessation. | Hughes JR et al. | — | 2007 | → |